KRW 18200.0
(0.94%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 3.68 Billion KRW | -69.34% |
2022 | 12.01 Billion KRW | -35.59% |
2021 | 18.65 Billion KRW | -17.8% |
2020 | 22.68 Billion KRW | -36.51% |
2019 | 35.73 Billion KRW | -14.81% |
2018 | 41.95 Billion KRW | 749.97% |
2017 | 4.93 Billion KRW | 393.55% |
2016 | 1 Billion KRW | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | 3.19 Billion KRW | -7.19% |
2024 Q1 | 3.44 Billion KRW | -6.41% |
2023 FY | 3.68 Billion KRW | -69.34% |
2023 Q2 | 2.36 Billion KRW | -10.46% |
2023 Q3 | 2.83 Billion KRW | 20.08% |
2023 Q4 | 3.68 Billion KRW | 29.78% |
2023 Q1 | 2.63 Billion KRW | -78.03% |
2022 Q2 | 18.6 Billion KRW | -0.15% |
2022 FY | 12.01 Billion KRW | -35.59% |
2022 Q4 | 12.01 Billion KRW | -35.9% |
2022 Q3 | 18.73 Billion KRW | 0.71% |
2022 Q1 | 18.63 Billion KRW | -0.08% |
2021 Q3 | 17.43 Billion KRW | 0.0% |
2021 FY | 18.65 Billion KRW | -17.8% |
2021 Q4 | 18.65 Billion KRW | 6.98% |
2020 FY | 22.68 Billion KRW | -36.51% |
2019 FY | 35.73 Billion KRW | -14.81% |
2018 FY | 41.95 Billion KRW | 749.97% |
2017 FY | 4.93 Billion KRW | 393.55% |
2016 FY | 1 Billion KRW | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
HLB Pharmaceutical Co., Ltd | 23.72 Billion KRW | 84.48% |
CMG Pharmaceutical Co., Ltd. | 19.74 Billion KRW | 81.348% |
Celltrion Pharm, Inc. | 162.52 Billion KRW | 97.734% |
Huons Global Co., Ltd. | 254.93 Billion KRW | 98.556% |
DongKook Pharmaceutical Co., Ltd. | 104.74 Billion KRW | 96.484% |
Enzychem Lifesciences Corporation | 5.65 Billion KRW | 34.903% |
Humedix Co., Ltd. | 2.7 Billion KRW | -36.302% |
Boditech Med Inc. | 10.56 Billion KRW | 65.153% |
EuBiologics Co., Ltd. | 14.77 Billion KRW | 75.082% |
Huons Co., Ltd. | 124.61 Billion KRW | 97.045% |
BNC Korea Co., Ltd. | 737.2 Million KRW | -399.527% |
AptaBio Therapeutics Inc. | 13.93 Billion KRW | 73.572% |